参考文献

[1]Torre L A, Bray F, Siegel R L, et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65:87-108.

[2]Rosell R, Karachaliou N.Large-scale screening for somatic mutations in lung cancer [J].Lancet,2016,387:1354-1356.

[3]MacMahon H, Austin J H, Gamsu G, et al.Guidelines for management of small pulmonary nodules detected on CT scans:a statement from the Fleischner Society [J].Radiology,2005,237:395-400.

[4]Mok T S, Wu Y L, Thongprasert S, et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361:947-957.

[5]Cancer Genome Atlas Research Network.Comprehensive molecular profiling of lung adenocarcinoma[J].Nature,2014,511:543-550.

[6]de Bruin E C, Cowell C, Warne P H, et al.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer[J].Cancer Discov,2014,4:606-619.

[7]Dong J, Phelps R G, Qiao R, et al.BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma[J].Cancer Res,2003,63:3883-3885.

[8]Engelman J A, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signaling[J].Science,2007, 316:1039-1043.

[9]Ludovini V, Bianconi F, Pistola L, et al.Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6:707-715.

[10]Sos M L, Koker M, Weir B A, et al.PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR[J].Cancer Res,2009, 69:3256-3261.

[11]Felip E, Hirsh V, Popat S, et al.Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase Ⅲ Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy[J].Clin Lung Cancer,2018,19:74-83.

[12]Gadgeel S, Goss G, Soria J C, et al.Evaluation of the VeriStrat®serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase Ⅲ LUX-Lung 8 study[J].Lung Cancer,2017,109:101-108.

[13]Thress K S, Paweletz C P, Felip E, et al.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J].Nat Med,2015,21:560-562.

[14]Subbiah V, Hong D S, Meric-Bernstam F.Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer:Bench to bedside report[J].Proc Natl Acad Sci U S A,2016,113:E1419-1420.

[15]Planchard D, Kim T M, Mazieres J, et al.Dabrafenib in patients with BRAF （V600E）-positive advanced non-small-cell lung cancer:a single-arm, multicentre, open-label, phase 2 trial[J].Lancet Oncol,2016,17:642-650.

[16]Chuang J C, Stehr H, Liang Y, et al.ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer:Response and Resistance to Targeted Therapies[J].J Thorac Oncol, 2017,12:833-842.

[17]Vaishnavi A, Capelletti M, Le A T, et al.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer[J].Nat Med,2013,19:1469-1472.

[18]Farago A F, Le L P, Zheng Z, et al.Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer[J].J Thorac Oncol,2015,10:1670-1674.

[19]Padda S, Neal J W, Wakelee H A.MET inhibitors in combination with other therapies in non-small cell lung cancer[J].Transl Lung Cancer Res,2012,1:238-253.

[20]Belalcazar A, Azana D, Perez C A, et al.Targeting the Met pathway in lung cancer [J].Expert Rev Anticancer Ther,2012,12:519-528.

[21]Ramalingam S S, Perol M, Reck M, et al.Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer:A Subgroup Analysis According to Patient Age in the REVEL Trial[J].Clin Lung Cancer,2017, pii:S1525-7304.

[22]Brunsvig P F, Aamdal S, Gjertsen M K, et al.Telomerase peptide vaccination:a phase Ⅰ/Ⅱstudy in patients with non-small cell lung cancer[J].Cancer Immunol Immunother,2006,55:1553-1564.

[23]Quoix E, Lena H, Losonczy G, et al.TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer（TIME）:results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial[J].Lancet Oncol,2016,17:212-223.

[24]Quoix E, Ramlau R, Westeel V, et al.Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer:a controlled phase 2B trial [J].Lancet Oncol,2011,12:1125-1133.

[25]Karnezis A N, Wang Y, Ramos P, et al.Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type[J].J Pathol,2016,238:389-400.

[26]Gao Y, Geng J, Hong X, et al.Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer[J].Int J Clin Exp Pathol,2014,7:760-767.

[27]de Bono J, Ramanathan R K, Mina L, et al.Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers[J].Cancer Discov,2017,7:620-629.

[28]Schwartz G K, LoRusso P M, Dickson M A, et al.Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles（Schedule 2/1）[J].Br J Cancer,2011,104:1862-1868.

[29]Herbst R S, Gandara D R, Hirsch F R, et al.Lung Master Protocol（Lung-MAP）-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer:SWOG S1400[J].Clin Cancer Res,2015,21:1514-1524.

[30]Scagliotti G, Kang J H, Smith D, et al.Phase Ⅱ evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer[J].Invest New Drugs,2016,34:625-635.

[31]Sahebjam S, Bedard P L, Castonguay V, et al.A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours（PJC-004/NCI 8503）[J].Br J Cancer,2013,109:943-949.

[32]Morgan K M, Fischer B S, Lee F Y, et al.Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma[J].Mol Cancer Ther,2017,16:2759-2769.

[33]McKeage M J, Kotasek D, Markman B, et al.Phase IB Trial of the Ant-i Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC[J].Target Oncol,2018,13:89-98.

[34]Paone A, Marani M, Fiascarelli A, et al.SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation[J].Cell Death Dis,2014,5:e1525.

[35]Zhang B, Zheng A, Hydbring P, et al.PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis[J].Cell Rep,2017,19:2289-2303.

[36]Labuschagne C F, van den Broek N J, Mackay G M, et al.Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells[J].Cell Rep,2014, 7:1248-1258.